Ivermectin and Hydroxychloroquine for Chemo-Prophylaxis of COVID-19: A Questionnaire Survey of Perception and Prescribing Practice of Physicians vis-a-vis Outcomes
Samajdar et al., Journal of the Association of Physicians India, 69:11
Physician survey in India with 164 ivermectin prophylaxis, 129 HCQ prophylaxis, and 81 control patients, showing significantly lower COVID-19 cases with treatment. Details of the treatment and control groups and the definition of cases are not provided, and the results are subject to survey bias. Authors also report on community prophylaxis but present only combined ivermectin/HCQ results.
52 studies are RCTs, which show efficacy with
p=0.00000021.
This study is excluded in the after exclusion results of meta
analysis:
minimal details provided; unadjusted results with no group details; results may be significantly affected by survey bias.
Study covers
HCQ and ivermectin.
|
risk of case, 79.8% lower, RR 0.20, p < 0.001, treatment 12 of 164 (7.3%), control 29 of 81 (35.8%), NNT 3.5, odds ratio converted to relative risk, physician survey.
|
|
risk of case, 48.6% lower, RR 0.51, p = 0.03, treatment 11 of 109 (10.1%), control 39 of 200 (19.5%), NNT 11, odds ratio converted to relative risk, combined ivermectin or HCQ in community.
|
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Samajdar et al., 17 Nov 2021, retrospective, India, peer-reviewed, 9 authors, study period 1 September, 2020 - 31 December, 2020, dosage not specified.
